Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Liver Int ; 44(8): 1971-1989, 2024 Aug.
Article in English | MEDLINE | ID: mdl-38634685

ABSTRACT

BACKGROUND AND AIMS: Decompensated-cirrhosis encompasses several stages with different prognosis, such as bleeding, ascites and bleeding-plus-ascites. Development of further-decompensation worsens survival, while non-selective ß-blockers (NSBBs) can modify the risk. However, how this applies to each stage is uncertain. We aimed to investigate, in each stage of decompensated-cirrhosis, the influence of further-decompensation on mortality and whether changes in portal-pressure (HVPG) under NSBBs influence these outcomes. METHODS: Patients with variceal bleeding were consecutively included differentiating those with bleeding-alone from those who also had ascites. Patients with ascites and high-risk varices referred for primary-prophylaxis were also investigated. A baseline haemodynamic study was performed and was repeated after 1-3-months under NSBBs. Outcomes were investigated by competing-risk. RESULTS: Totally 103 patients had bleeding-alone, 186 bleeding-plus-ascites and 187 ascites-alone. Mean follow-up was 32-months (IQR, 12-60). Patients with bleeding-plus-ascites had higher HVPG and were more hyperdynamic than patients with ascites-alone and these than those with bleeding-alone. At each stage, the mortality risk was more than twice in patients developing further-decompensation vs. those without (p < .001). In each stage, HVPG-decrease under NSBBs showed better discrimination to predict further-decompensation than the baseline MELD, Child-Pugh or HVPG, by time-dependent ROC-curves (c-statistic >70%). At each stage, patients without HVPG-decreases, either ≥10% or ≥20% from the baseline, had higher risk of further-decompensation (sHR from 2.43 to 6.73, p < .01) and worse survival. CONCLUSIONS: In each stage of decompensated cirrhosis, mortality risk significantly and very markedly increase with further-decompensation. HVPG-non-response to NSBBs may adequately stratify the risk of further decompensation and death, in each stage. This suggests potential benefit with pre-emptive therapies in HVPG-non-responders at each-stage.


Subject(s)
Ascites , Esophageal and Gastric Varices , Gastrointestinal Hemorrhage , Hypertension, Portal , Liver Cirrhosis , Portal Pressure , Humans , Hypertension, Portal/physiopathology , Hypertension, Portal/mortality , Hypertension, Portal/etiology , Liver Cirrhosis/complications , Liver Cirrhosis/mortality , Liver Cirrhosis/physiopathology , Female , Male , Ascites/physiopathology , Ascites/mortality , Ascites/etiology , Middle Aged , Gastrointestinal Hemorrhage/mortality , Gastrointestinal Hemorrhage/etiology , Gastrointestinal Hemorrhage/physiopathology , Esophageal and Gastric Varices/mortality , Esophageal and Gastric Varices/physiopathology , Esophageal and Gastric Varices/etiology , Aged , Prognosis , Adrenergic beta-Antagonists/therapeutic use , ROC Curve
SELECTION OF CITATIONS
SEARCH DETAIL
...